Background: We wanted to determine whether neoadjuvant systemic chemoendocrine therapy guided by the estrogen receptor (ER) status of the primary breast cancer, followed by conventional surgery and/or radiotherapy, reduces local and distant recurrence and improves survival compared with adjuvant treatment given conventionally postoperatively.
Introduction
Previous studies have demonstrated that primary chemotherapy [1] [2] [3] and primary endocrine therapy [4] [5] [6] are effective in reducing the size of primary breast cancers.
Our initial studies compared chemotherapy with endocrine therapy in a group of patients in whom the ER status was not known [7] . Subsequently, we and others developed the methodology for immunostaining for ER [8, 9] and we subsequently applied this technique to enable us to select patients for either endocrine therapy or chemotherapy [10] .
In this study [10] , we found that pre-treatment with neoadjuvant therapy in all stages of primary breast cancer (T^T,,, N o , Ni or N 2 ) leads to a 40% response in ER positive tumours and a 60% response in ER negative tumours. This confirmed an earlier trial in locally advanced breast cancer [7] , which also suggested that pre-treatment might significantly down-stage primary breast cancer.
In designing the study outlined in this report we attempted to determine whether it is possible to use the primary tumour as an aid to select systemic adjuvant therapy for micrometastases after the pre-surgical ('neoadjuvant') therapy period. Thus, in addition to selecting neoadjuvant therapy on the basis of the ER status, we attempted to select adjuvant therapy on the basis of the initial reduction in tumour size observed in the presurgical period. Hence, patients with ER positive tumours who failed to respond to first-line endocrine therapy went on to receive adjuvant chemotherapy after surgery. Patients with ER negative tumours who failed to respond to first-line chemotherapy went on to receive second-line chemotherapy after surgery. 
Patients Randomised
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This current report, an extension of the previous trial, examines the effect of pre-treatment on subsequent management and the longer-term outcome of treatment with a minimum of five years follow-up.
Patients and methods
We randomised 210 patients (see flow chart, Figure 1 ) with breast cancer aged between 30 and 69 (mean 54 years) attending the Combined Breast Clinic at St. George's Hospital between 1990 and 1993. This was confirmed by mammography and fine needle aspiration cytology (FNAC). No patients had evidence of metastases on standard screening [13] which included chest radiography, bone scan, liver ultrasound, full blood count and liver function tests. We excluded patients over 70 years of age, patients with significant cardiac or renal impairment, and those with any previous history of cancer All patients were fully informed of the objectives of the trial Those joining the trial gave written consent in every case according to the Helsinki agreement. Randomisation was by envelope All patients without evidence of melastases proceeded to a Trucut biopsy of the tumour to confirm the presence of an invasive ductal or lobular carcinoma. All other tumours including non-invasive carcinoma, ductal breast carcinoma in situ (DCIS) and lobular breast carcinoma in silu (LCIS) were excluded from the trial and treated appropriately Those patients who on Trucut biopsy had a ER-positive invasive carcinoma (more than 30% of carcinoma cells staining positive using immunohisto-chemistry) received endocrine treatment; premenopausal goserelin (a leuteinising hormone releasing hormone (LHRH) agonist leuprolide) 3.75 mg, subcutaneously every four weeks; or postmenopausal -4 hydroxyandrostenedione (formestane), 250 mg. l.m. ever)' two weeks. Those All patients were clinically assessed at three-to four-weekly intervals Tumour size was measured, prior to randomisation, preoperatively. with calipers by bidimensional measurements and the area calculated as the product of these two measurements. All patients had a preliminary mammogram before treatment and a second mammogram 12 weeks before definitive surgery and radiotherapy. All responders were assessed according to standard UICC criteria and toxicity according to WHO grading.
Surgical and radiotherapeutic treatment of the primary tumour was decided using identical criteria in both arms of the study. They were advised to have primary conservative surgery (wide local excision and Level 1 axillary dissection) or mastectomy depending on the T-stage. Where the tumour was clinically less than 5 cm (T,, T 2 ), if appropriate, conservative surgery was performed followed by radiotherapy to the breast including a boost to the scar area. Axillary node positive patients received additional radiotherapy to the axilla and supraclavicular fossa. All patients with tumours in the medial half of the breast had. in addition, radiotherapy to the ipsilateral internal mammary chain. If the tumour was greater than 5 cm in diameter (Tj. T 4 ) and radical or conservative surgery was not appropriate, the patients had primary radiotherapy to the breast with appropriate boost to the tumour sue where indicated. The axilla was irradiated where the axillary nodes were clinically positive (T 3 4 . N, 2 ) When radiotherapy did not produce a response (NC or PD). where possible, a mastectomy was performed.
Patients in the neoadjuvant arm of the study who had responded, received a total of 8 cycles MMM chemotherapy or 18 months endocrine therapy using Goserelin (3.75 mg/month) or formestane (250 mg every two weeks). Conventionally treated patients received adjuvant therapy based on the ER and menopausal status as for the pre-treatment group, i.e., ER positive patient received endocrine therapy (as above) for 18 months and ER negative patients received a further 4 courses to make a total of 8 courses of MMM chemotherapy. Those patients who failed to respond to neoadjuvant therapy, received secondline treatment postoperatively, i.e., MMM chemotherapy (8 cycles) in Abbreviations' pN 0 -no histopathological evidence of involvement; pN, -histopathological evidence of node involvement.
the ER positive patients, and FEC (5-fluorouracil 600 mg/m 2 , epirubicin 50 mg/m 2 ; cyclophosphamide 600 mg/m 2 given every three weeks) chemotherapy for a total of eight cycles in the ER negative patients
Statistical considerations
The sample size for this single centre pilot study was pragmatic with the aim being to recruit as many patients as possible With 210 patients eventually randomised the study was not statistically powered to detect moderate improvements in risk of recurrence, breast cancer death or numbers undergoing conservation surgery but did have 80% power to detect larger differences of, e.g , 25% to 15% at P < 0.05. Baseline characteristics were compared using the Mantel Haenszel test and survival by standard log-rank methods [II, 12] .
Results
We have previously reported the clinical assessment at 12 weeks of the 100 patients allocated neoadjuvant chemo-endocrine therapy [10] . Fifty-three patients who were ER negative received MMM with a clinical response of 60% and complete clinical response of 34%. The 47 patients who were ER positive had an overall response rate of 53.8% (7 of 13) for Goserelin and 35% (12 of 34) for formestane. Thus 51 patients responded to neoadjuvant treatment. In the neoadjuvant group, there were 34 T, and 40 T 2 (74 T|/T 2 ) tumours. At 12 weeks, there were 32 T, and 32 T 2 (64 T, /T 2 ) a down-staging of 10%. There were 26 T 3 /T 4 tumours. Nine (35%) decreased in size with two complete responses; in eleven (42%) there was no change and in a further six (23%) there was progressive disease.
These patients constituted the neoadjuvant arm of a randomised study of 210 patients and this entire group forms the basis of this report after a minimum of five year follow-up. The two groups were well matched (Table 1) , both by age, menopausal status and node involvement.
Effect of neoadjuvant therapy on survival and time to recurrence
There was no significant difference in the number of events (local and/or distant recurrence) at two and five years' follow-up. However, in the ER negative (chemotherapy) group, the pre-treatment patients fared a little worse than those not pre-treated in terms of both survival and recurrence. But these differences were not statistically significant. The graphical analysis of the data shows no difference in survival, or time to local or distant recurrence (Figures 2-4) .
Effect of neoadjuvant treatment on subsequent treatment
Twenty-five of one hundred patients had a complete response and twenty-six a partial response from preoperative chemoendocrine therapy (Table 2 ). In the complete response category, only ten patients (40%.) had a palpable lesion and required a wide local excision; eight patients still had a radiological abnormality and required radiological localisation and excision. Four were treated by radiotherapy alone. Thus, 60% had a down grade of the type of surgery they would have had, had they not had pre-operative chemoendocrine therapy, but 21 of 25 patients still required to have the residual tumour excised. 
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Local recurrence (13) T,/T 2 T3/T4 All 51 patients who showed complete or partial response continued with chemotherapy (8 cycles or MMM) or endocrine therapy for 18 months with leuprolide or formestane as appropriate. Forty-nine patients (21 pre MMM, 6 pre leuprolide and 22 pre-formestane) had no change (NC) (n = 32) or progressive disease (PD) (n = 17) at three months assessment of pre-treatment. These patients are considered in more detail. Thirteen patients who had received neoadjuvant MMM had surgery (10 wide local excision followed by radiotherapy, 3 mastectomy) and two patients radiotherapy (T4B/T4C tumours). Four continued on MMM in view of a minimum response, nine changed to FEC and two refused further chemotherapy and were given tamoxifen. All had postoperative radiotherapy.
All but one of the 17 patients who had received neoadjuvant endocrine therapy had surgery (14 wide local excision, 2 mastectomy) whilst one patient (T 3 A tumour) had radiotherapy. Two patients refused further systemic therapy, three elected to continue on hormonal therapy in view of the slide effects profile of chemotherapy and twelve received MMM.
Subsequent adjuvant therapy in patients showing progressive disease
Seventeen patients had progressive disease (6 neoadjuvant MMM, 2 neoadjuvant goserelin and 9 neoadjuvant formestane). Six patients who had neoadjuvant MMM had surgery (3 wide local excision, 3 mastectomy) followed by FEC in five (1 patient refused further chemotherapy and received tamoxifen). Eight patients who had neoadjuvant formestane had surgery (6 wide local excision, 2 mastectomy), 1 received radiotherapy (T 3 A tumour). Eight received MMM and one tamoxifen. The two patients who had neoadjuvant goserelin both received MMM, after mastectomy (n = 1) or wide local excision (n = 1). All patients received radiotherapy.
Relationship of response to neoadjuvant therapy and outcome
At 5 years follow-up, 11 (23%) patients with local recurrences and 17 (35%) patients with distant metastases, were seen in the 49 patients who had no change (NC) or progressive disease (PD) compared with the 9 local recurrences (18%) and 4 (81%) distant metastases seen in the 51 patients who had a complete or partial remission (CR/PR). There was significant difference in the incidence of distant metastases depending on response
The number in brackets is the total number in each group.
Effects of neoadjuvant treatment on extent of surgery
We examined the possibility that pre-treatment with chemoendocrine therapy downgrades the extent of subsequent primary surgical or radiotherapeutic treatment (Table 3 ). In the T,_ 2 group, 86% (64 of 74) of patients treated with neoadjuvant chemoendocrine therapy re- 1 All primary became impalpable. ' Two of these became impalpable quired some form of surgery, compared with 100% in the adjuvant group. In theT 3^, group, 77% (20 of 26) of the neoadjuvant group had some form of surgery compared with 84% (21 of 25) in the adjuvant group. Thus there was a significant reduction in the need for surgery in the patients with smaller carcinomas, with a greater use of radiotherapy on the sole treatment modality in the neoadjuvant group (P < 0.01).
Side effects of systemic therapy
The systemic therapy outlined here was well tolerated and side effects have been previously documented [10] . The 51 patients who had a complete or partial response all completed their chemotherapy. Side effects over the entire course mostly took the form of lethargy (79%) (grade 3-4, 30%), nausea (70%) (grade 3-4, 13%) alopecia (70%) (grade 3-4, 10%) and stomatitis (64%) (grade 3-4, 9%) although the majority had only mild side effects. Similarly, the overall incidence of sideeffects in the endocrine therapy-treated group were as previous described: lethargy (19%) (grade 3-4, 10%): nausea (5%) (grade 3-4, 2%): other side effects including hot flushes, were grade 1-2 and occurred in 16% of patients.
Discussion
Our study is the first neoadjuvant study to report treatment outcome for patients selected for neoadjuvant endocrine and chemotherapy based on pre-treatment ER estimation. In addition, it is the first study to report the use of neoadjuvant aromatase inhibitors as primary endocrine therapy in a randomised trial. The results of this study indicated that, in line with other neoadjuvant studies [14] , neoadjuvant therapy fails to confer any survival benefit to patients who receive it when compared to those who received therapy post-operatively in a conventional manner. We also failed to find a benefit, despite selecting systemic therapy on the basis of the ER content of the primary tumour and postoperative therapy depending on the response observed in the pre-surgical period.
The rationale for selecting the specific neoadjuvant therapies were based on several considerations; 4-hydroxyandrostenedione (formestane) had been shown to be a specific aromatase inhibitor [15] and not subject to 'tumour flare' as observed sometimes with tamoxifen. We gave patients 18 months treatment because our previous experience [16] showed that this length of therapy was the maximum tolerable by patients. We also reasoned that aromatase inhibitors may lead to more rapid primary tumour shrinkage since blood levels of tamoxifen take time to accumulate. In contrast, formestane, like other third generation aromatase inhibitors, suppresses plasma estradiol within two to three days [16] . Furthermore, studies carried out have shown that formestane leads to an equivalent response rate to those receiving tamoxifen.
The rationale for selecting an LHRH agonist for the pre-menopausal women was to achieve oestrogen deprivation as rapidly as possible. We accept that, like tamoxifen, there could be a 'tumour flare' with this form of treatment due to LH and FSH release. However, no evidence of this was seen in our patients and rapid reduction of tumour mass was seen.
The rationale for selecting the MMM regimen was based on our previous experience [17, 18] ) which showed this regimen to be extremely well-tolerated with good anti-tumour activity. A major consideration was the fact that this regime is not often complicated by grade 3-4 alopecia, frequently observed in patients receiving adriamycin-cyclophosphamide combinations as described in the NSABP neoadjuvant study [14] . Smith and Ellis [19] have suggested that the use of primary chemotherapy represents a novel approach being used with increasing frequency in the management of early breast cancer. The suggestion from their review of current literature is that it leads to an increasing use of conservative surgery which we have confirmed for chemotherapy and now also shown for endocrine therapy.
Our finding that a response is associated with a better outlook is consistent with another report [21] who found that survival at ten years following pre-operative chemoendocrine therapy was associated with a survival advantage in those who had a primary response. However, they noted that the number of involved axillary nodes was the best discriminant with all node negative patients having a similar survival irrespective of the primary tumour pathological response. It was possible to detect a group of women who had a very poor prognosis. In fact in their series of 94 patients, none of the 24 patients with 4 or more positive nodes survived 10 years. Five of twenty-six patients with one to three nodes positive and twelve of forty-four node-negative patients survived ten years.
The overview of the NSABP neoadjuvant chemotherapy trial [22] , noted clear evidence that the admin-istration of pre-treatment chemotherapy resulted in a pathologic axillary lymph node downstaging. Whereas 58% of the patients receiving post operative chemotherapy were found at surgery to have pathologically positive lymph nodes, only 40% of patients receiving pre-operative chemotherapy were found to have nodal involvement. The difference was statistically significant (P < 0.01). In our study of 210 patients with a histologically proven invasive carcinoma, in the pre-treatment group, 29% who had neoadjuvant therapy were found to have pathologically positive axillary lymph nodes compared with 40% in the post-operative chemotherapy group; a non-significant finding perhaps because of the smaller numbers (Table 1) .
In the NSABP series of 1523 patients from eleven centres, the diagnosis of breast cancer was by fine needle aspiration (FNA) or core needle biopsy. It has been our experience of FNA that it is not a reliable diagnostic method of differentiating between ductal carcinoma in situ and invasive carcinoma. This may be a factor in the number of patients found with non-invasive carcinoma or no invasive carcinoma after chemotherapy. This could affect the incidence of positive lymph nodes found at surgery.
What are the implications of our study for the future design of neoadjuvant studies? Firstly, we have found that oestrogen withdrawal therapy can be safely given to patients with breast cancer prior to surgery since this does not adversely effect their survival. Similarly, MMM, a relatively well-tolerated regimen, can be given and results in substantial tumour reduction. It seems to us, therefore, that these forms of treatment need to be compared for efficacy and side effects with more conventional endocrine therapy (e.g., tamoxifen) and chemotherapy (e.g., adriamycin, cycophosphamide and/or taxanes) in the neoadjuvant setting.
Secondly, we have demonstrated that it is possible to switch therapies in the subgroup of patients who failed to respond to neoadjuvant therapy. Further studies are required to determine the impact of using the primary tumour as a tumour marker in systemic therapy selection in much larger trials. Although we removed the primary tumour at three months, it may be that we should only remove it when we have used its presence to define the most suitable systemic therapy; or if there is demonstrated resistance to available cytotoxic or endocrine drug combinations. This study was commenced before taxanes were in use in breast cancer management: our recent pilot study has shown a profound effect of single-agent Taxol in the neoadjuvant setting [24] ,
